XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells

We recently identified superoxide dismutase (SOD) overexpression and decreased induction of reactive oxygen species (ROS)-mediated apoptosis in models of inflammatory breast cancer (IBC) cells with acquired therapeutic resistance. This population of cells has high expression of X-linked inhibitor of apoptosis protein (XIAP), which inhibits both extrinsic and intrinsic apoptosis pathways. We therefore wanted to evaluate the effect of classical apoptosis-inducing agent TRAIL, a proapoptotic receptor agonist that selectively triggers death receptor (DR)-mediated apoptosis in cancer cells, in the IBC acquired resistance model. XIAP levels and subsequent inhibition of caspase activity inversely correlated with TRAIL sensitivity in our models of IBC. These include SUM149, a basal-type cell line isolated from primary IBC tumors and isogenic SUM149-derived lines rSUM149 and SUM149 wtXIAP, models of acquired therapeutic resistance with endogenous and exogenous XIAP overexpression, respectively. Inhibition of XIAP function using embelin, a plant-derived cell permeable small molecule, in combination with TRAIL caused a synergistic decrease in cell viability. Embelin treatment resulted in activation of extracellular signal–regulated kinase (ERK)1/2 and ROS accumulation, which correlated with downregulation of antioxidant protein SOD1 and consumption of redox modulator reduced glutathione in the XIAP-overexpressing cells. Simultaneous treatment with an SOD mimic, which protects against ROS accumulation, reversed the decrease in cell viability caused by embelin + TRAIL treatment. Embelin primes IBC cells for TRAIL-mediated apoptosis by its direct action on the anti-caspase activity of XIAP and by shifting the cellular redox balance toward oxidative stress–mediated apoptosis. Thus, ROS modulators represent a novel approach to enhance efficacy of TRAIL-based treatment protocols in IBC. Mol Cancer Ther; 11(7); 1518–27. ©2012 AACR.

[1]  T. Fouad.  Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population‐based study , 2012, Cancer.

[2]  Mark W. Dewhirst,et al.  ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells , 2012, Breast Cancer Research and Treatment.

[3]  M. Dewhirst,et al.  Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. , 2011, Free radical biology & medicine.

[4]  Karsten Juhl Jørgensen,et al.  Reply to differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population‐based study , 2011, Cancer.

[5]  W. Woodward,et al.  Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early , 2011, Cancer.

[6]  H. Gollnick,et al.  Cellular FLICE-inhibitory Protein (cFLIP) Isoforms Block CD95- and TRAIL Death Receptor-induced Gene Induction Irrespective of Processing of Caspase-8 or cFLIP in the Death-inducing Signaling Complex* , 2011, The Journal of Biological Chemistry.

[7]  S. Fulda,et al.  Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma , 2011, Clinical Cancer Research.

[8]  M. Mi,et al.  3,6-Dihydroxyflavone induces apoptosis in leukemia HL-60 cell via reactive oxygen species-mediated p38 MAPK/JNK pathway. , 2010, European journal of pharmacology.

[9]  Melissa Bondy,et al.  Inflammatory Breast Cancer: The Disease, the Biology, the Treatment , 2010, CA: a cancer journal for clinicians.

[10]  V. Stagni,et al.  ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. , 2010, Carcinogenesis.

[11]  B. Aggarwal,et al.  Gossypol Induces Death Receptor-5 through Activation of the ROS-ERK-CHOP Pathway and Sensitizes Colon Cancer Cells to TRAIL* , 2010, The Journal of Biological Chemistry.

[12]  Sharon Peplinski,et al.  X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[13]  N. Navaratnam,et al.  AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators. , 2010, Biochemical pharmacology.

[14]  J. Thompson,et al.  Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA , 2010, Molecular Cancer Therapeutics.

[15]  J. Chambard,et al.  ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence , 2010, The FEBS journal.

[16]  T. Griffith,et al.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. , 2009, European journal of pharmacology.

[17]  B. Aggarwal,et al.  Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. , 2009, Cancer research.

[18]  T. Hei,et al.  Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. , 2009, Cancer research.

[19]  S. Cook,et al.  Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.

[20]  J. McCubrey,et al.  Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. , 2008, Cancer research.

[21]  S. Wang,et al.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway , 2008, Oncogene.

[22]  H. Walczak,et al.  Death receptors as targets for anti-cancer therapy , 2008, Journal of cellular and molecular medicine.

[23]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Gollnick,et al.  Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis , 2008, Oncogene.

[25]  P. Meltzer,et al.  TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype , 2008, Breast Cancer Research and Treatment.

[26]  Xinyu Zhao,et al.  Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. , 2008, Leukemia research.

[27]  K. Aird,et al.  Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression , 2008, Molecular Cancer Therapeutics.

[28]  D. El-Ashry,et al.  Reversal of the Estrogen Receptor–Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response , 2007, Clinical Cancer Research.

[29]  B. Aggarwal,et al.  Embelin, an Inhibitor of X Chromosome-Linked Inhibitor-of-Apoptosis Protein, Blocks Nuclear Factor-κB (NF-κB) Signaling Pathway Leading to Suppression of NF-κB-Regulated Antiapoptotic and Metastatic Gene Products , 2007, Molecular Pharmacology.

[30]  R. Schnellmann,et al.  A Death-Promoting Role for Extracellular Signal-Regulated Kinase , 2006, Journal of Pharmacology and Experimental Therapeutics.

[31]  Zhimin Lu,et al.  ERK1/2 MAP kinases in cell survival and apoptosis , 2006, IUBMB life.

[32]  Susanne J. Braeuer,et al.  Constitutively Activated Nuclear Factor-κB, but not Induced NF-κB, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells , 2006, Molecular Cancer Research.

[33]  E. Agostinelli,et al.  Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications , 2006, Amino Acids.

[34]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[35]  P. Iversen,et al.  X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. , 2004, Molecular Cancer Therapeutics.

[36]  Dajun Yang,et al.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004, Journal of medicinal chemistry.

[37]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[38]  S. Shankar,et al.  Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  O. Micheau.  Cellular FLICE-inhibitory protein: an attractive therapeutic target? , 2003, Expert opinion on therapeutic targets.

[40]  A. Chinnaiyan,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  O. Kallioniemi,et al.  Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.

[43]  K. Todokoro,et al.  Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. , 1999, Blood.

[44]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[45]  E. Sukumar,et al.  Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. , 1994, Chemotherapy.

[46]  A. Maiti.  Genetic determinants of oxidative stress‐mediated sensitization of drug‐resistant cancer cells , 2012, International journal of cancer.

[47]  Eric J. W. Visser,et al.  Abramoff MD, Magalhaes PJ, Ram SJ. 2004. Image Processing with ImageJ. Biophotonics , 2012 .

[48]  B. Aggarwal,et al.  Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. , 2007, Molecular pharmacology.

[49]  D. Vaux,et al.  XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland , 2005, Cell Death and Differentiation.

[50]  B. Aggarwal,et al.  Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. , 2004, Vitamins and hormones.

[51]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[52]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.